Posted by Social Science Research Network
Optimal incentives for patent challenges in the pharmaceutical industry
By Enrico Boehme, Jonas Severin Frank & Wolfgang Kerber (University Marburg)
Abstract: Since the patent system relies on private litigation for challenging weak patents, and patent settlements might influence the incentives for challenging patents, the question arises whether the antitrust assessment of patent settlements should also consider their impact on the incentives to challenge potentially invalid patents. Patent settlements in the pharmaceutical industry between originator and generic firms have been scrutinized critically by competition authorities for delaying the market entry of generics and therefore harming consumers. In this paper we present a model that analyzes the tradeoff between limiting the delay of generic entry through patent settlements and giving generic firms more incentives for challenging weak patents of the originator firms. We show that allowing patent settlements with a later market entry of generics than the expected market entry under patent litigation can increase consumer welfare under certain conditions. We introduce a policy parameter for determining the optimal additional period for collusion that would maximize consumer welfare and show that the size of this policy parameter depends on the size of the challenging costs, the intensity of competition, and the duration between the generics’ market entry decisions.
Featured News
NCAA and SEC Approve Historic $2.8 Billion Settlement in Antitrust Cases
May 23, 2024 by
CPI
Apple Defends 27% Fee in Compliance with Court Order, Phil Schiller Testifies
May 23, 2024 by
CPI
French Billionaire Xavier Niel Eyes $4 Billion Millicom Buyout
May 23, 2024 by
CPI
ITA-Lufthansa Merger Faces Scrutiny from European Commission
May 23, 2024 by
CPI
Google Explores Major Acquisition of HubSpot to Bolster Cloud
May 23, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI